

CD τ ϵ EXPRESSION AS MARKER OF MONOCYTIC DIFFERENTIATION IN ACUTE MYELOID LEUKEMIA

Thesis

***Submitted for Partial Fulfillment of Master Degree
In Clinical and Chemical Pathology***

By

Soha Abd Elkareem Hamed Mahmoud

M.B.,B.Ch

Faculty of Medicine - Ain Shams University

Under Supervision of

Professor / Hala Mahmoud Hamdy Abaza

Professor of Clinical Hematology

Faculty of Medicine - Ain Shams University

Doctor / Hanan Mohamed Mahmoud

Assistant Professor of Clinical and Chemical Pathology

Faculty of medicine - Ain Shams University

**Faculty of Medicine
Ain Shams University**

٢٠١٣

ظهور سي دي ٦٤ كميز لخلايا الوحيدات والوحيدات
الاولية في ابيضاض الدم النقوي الحاد

رسالة

توطئة للحصول علي درجة الماجستير في
الباثولوجيا الإكلينيكية والكيميائية

مقدمة من

الطبيبة / سها عبد الكريم حامد محمود

بكالوريوس الطب والجراحة العامة - كلية الطب - جامعة عين شمس

تحت إشراف

الأستاذ الدكتور/هالة محمود حمدي اباطة

أستاذ امراض الدم الإكلينيكية

كلية الطب - جامعة عين شمس

الدكتور/ حنان محمد محمود

أستاذ مساعد الباثولوجيا الإكلينيكية والكيميائية

كلية الطب - جامعة عين شمس

كلية الطب

جامعة عين شمس

٢٠١٣



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ
"قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا
إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ"

صدق الله العظيم

سورة البقرة الآية (٣٢)

List of Contents

	<u>Page</u>
Acknowledgement	I
List of Abbreviations	II
List of Tables	V
List of Figures	VIII
 Introduction	 ١
aim of the work.....	٣
 Review of Literature:	
I - Acute myeloid leukemia	٤
II- the CD٦٤ (fc-gamma-receptor ١)	٥٠
 Subjects and methods	 ٥٩
 Results	 ٧٠
 Discussion.....	 ٩٧
 Summary.....	 ١٠٧
 Conclusion	 ١١٣
 Recommendations	 ١١٤
 Future directions	 ١١٥
 References	 ١١٦

Acknowledgement

*First of all, I would like to express my deep gratitude to **GOD** for his care and generosity throughout my life.*

*I would like to express my sincere appreciation to **Prof. Dr. Hala Mahmoud Hamdy Abaza**, Professor of Clinical Hematology, Faculty of Medicine, Ain Shams University for her keen supervision and guidance and her overwhelming support that has been of great help throughout this work.*

*I am very thankful to **Dr. Hanan Mohamed Mahmoud** Lecturer of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University for her great support & effort throughout the whole work.*

*And I would like to dedicate to my **Husband** and To **My Mother**, for their continuous encouragement and for pushing me forward.*

*And To **The Soul of My Father**.*

Soha Abd Elkareem Hamed

List Of Abbreviations

ADH	: Anti diuretic hormone
Ag	: Antigen
AML	: Acute myeloid leukemia
ANLL	: Acute non lymphocytic leukemia
APL	: Acute promyelocytic leukemia
ATRA	: All trnasretinoic acid
BAALC	: Brain and acute leukemia cytoplsmic gene
Bcl-γ	: B-cell lymphoma γ
BM	: Bone marrow
Ca	: Calcium
CAE	: Chloroacetate esterase
CBC	: Complete blood count
CBFβ	: Core binding factor β
CD	: Cluster of differentiation
CEBPA	: CCAAT/enhancer binding protein alpha
CGH	: Comparative genomic hybridization
C-KIT	: Steal factor
CML	: Chronic myeloid leukemia
CMV	: Cytomegalovirus
CNS	: Central nervous system
CR	: Complete remission
CRD γ	: First complete remission
DIC	: Disseminated intravascular coagulopathy
DNA	: Deoxy ribonucleic acid
EM	: Electron microscope
EPO	: Erythropoietin
FAB	: French –American –British classification
FAB-Mγ	: Minimally differentiated acute myeloblastic leukemia
FAB-Mγ	: Acute myeloblastic leukemia, without maturation
FAB-Mγ	: Acute myeloblastic leukemia, with granulocytic maturation
FAB-Mγ	: Acute promyelocytic leukemia
FAB-Mδ	: Acute myelomonocytic leukemia
FAB-M\circ	: Acute monoblastic leukemia
FAB-Mγ	: Erythroblastic leukemia
FAB-Mγ	: Acute megakaryoblastic leukemia
FcγR	: Fc-gamma-receptor
FISH	: Fluorescence in-situ hybridization

List Of Abbreviations (Cont.)

FLT³	: Fms-like tyrosine kinase ³
FMF	: Familial mediterranean fever
G-CSF	: Granulocyte –colony stimulating factors
GM-CSF	: Granulocyte-monocyte-colony stimulating factor
GVHD	: Graft versus host disease
HB	: Hemoglobin
HCT	: Hematopoietic stem cell transplantation
HGFs	: Hematopoietic growth factors
HLA	: Human leucocytic antigen
IFN-γ	: Interferon-gamma
Ig	: Immunoglobulines
IL	: Interleukin
IPT	: Immunophenotyping
ITDs	: Internal tandem duplications
K	: Potassium
LDH	: Serum lactate dehydrogenase
LM	: Light microscope
LN	: Lymph node
M-CSF	: Monocyte–colony stimulating factor
MDR	: Multidrug resistance
MDS	: Myelodysplastic syndrome
M-FISH	: Multicolor FISH
MLL	: Myeloid/lymphoid gene
MM	: Multiple myeloma
MoAb	: Monoclonal antibodies
MPD	: Myelo-proliferative disease
MPO	: Myeloperoxidase
MRD	: Minimal residual disease
Na	: Sodium
NEC	: Non erythroid cells
NPM	: Nucleophosmin
NSE	: Non specific esterase
PAS	: Periodic acid Schiff
PB	: Peripheral blood
PBSC	: Peripheral blood stem cells
PCR	: Polymerase chain reaction
PDGF-R	: Platelet derived growth factor receptor
Pgp	: P-glycoprotein

List Of Abbreviations (Cont.)

PMNs	: Polymorph nuclear leucocytes
PRINS	: Primed in situ hybridization
PT	: Prothrombin time
PTT	: Partial thromboplastin time
RARA	: Retinoic acid receptor alpha
RB	: Retinoblastoma protein
RBC	: Red blood cell
RNA	: Ribonucleic acid
RT-PCR	: Reverse transcriptase PCR
SB	: Sudan black stain
SCL	: Stem cell leukemia
SCT	: Stem cell transplantation
SD	: Standard deviation
SKY	: Spectral karyotyping
SLE	: Systemic lupus erythematosus
SN	: Significance
TdT	: Terminal deoxynucleotidyl transferase
TLC	: Total leucocytic count
TNF-α	: Tumor necrosis factor- α
Topo II	: Topoisomerase II
TSG	: Tumor suppressor genes
VEGF	: Vascular endothelial growth factor
vWF	: Von Willebrand factor
WBC	: White blood cell
WHO	: World health organization
WT-1	: Wilms tumor-1 gene

List of Tables

	<u>Page</u>
Table ١: The FAB Classification of AML	١٢
Table ٢: Immunophenotypic markers of AML	١٥
Table ٣: MIC classification of AML associating morphology (FAB) with cytogenetics and IP	١٦
Table ٤: WHO Classification of AML and related neoplasms	١٧
Table ٥: Cytochemistry of AML.....	٢٧
Table ٦: Panel of MoAbs to differentiate AML and ALL	٢٨
Table ٧: Immunologic phenotypes of AML.....	٢٩
Table ٨: Scoring system for the diagnosis of biphenotypic acute leukemia	٣٠
Table ٩: Most Common Significant Chromosomal Abnormalities in AML	٣٢
Table ١٠: Gene mutations in patients with AML and normal karyotype	٣٤
Table ١١: Recurrent clinically significant genes whose mutations or changes in expression occur in cytogenetically normal AML	٣٥
Table ١٢: Prognostic factors in AML	٣٧
Table ١٣: Prognostic subgroups of AML based on the presenting cytogenetics and genetic lesions	٣٨
Table ١٤: Guidelines for supportive care in patients with AML.	٤١
Table ١٥: Categories of Novel therapies in AML.....	٤٥
Table ١٦: Methods for the detection of MRD in AML.....	٤٩
Table ١٧: Demographic data of studied AML patients.....	٨٠

List of Tables (Cont.)

	<u>Page</u>
Table ١٨: Clinical data of studied AML patients	٨٠
Table ١٩: The relationship between prognosis and clinical data among the AML patients	٨٢
Table ٢٠: The relationship between lab data of the studied AML patients and prognosis	٨٣
Table ٢١: Laboratory data of studied AML patients	٨٤
Table ٢٢: Statistical analysis of lab data of the studied AML patients	٨٥
Table ٢٣: The relationship between prognosis and cytogenetics of the studied AML patients	٨٥
Table ٢٤: Best cut-off value of CD٦٤ for the prediction of good prognosis	٨٦
Table ٢٥: CD٦٤ expression, outcome and response to therapy in studied AML patients	٨٧
Table ٢٦: CD٦٤ expression in the studied AML group versus the controls	٨٨
Table ٢٧: CD٦٤ expression in AML patients	٨٨
Table ٢٨: Comparison of CD٦٤ expression among FAB subtypes	٩٠
Table ٢٩: CD٦٤ expression in monocytic versus non-monocytic groups of studied AML patients	٩١
Table ٣٠: Correlation between CD٦٤ expression & different clinical & lab parameters in AML patients	٩٢
Table ٣١: CD١٤, CD١٥ and CD٦٤ expression in AML-M٤ and M٥ subgroups	٩٣
Table ٣٢: CD١٤ expression in monocytic versus non-monocytic	

groups of studied AML patients	٩٤
--------------------------------------	----

List of Tables (Cont.)

	<u>Page</u>
Table ٣٣: CD١٥ expression in monocytic versus non- monocytic groups of studied AML patients	٩٤
Table ٣٤: Clinical and lab parameters of monocytic versus non-monocytic groups of studied AML	٩٥
Table ٣٥: Multivariate analysis of different prognostic factors related to clinical outcome in studied AML patients	٩٦

List of Figures

	<u>Page</u>
Figure ١: Leukemia cutis manifesting as subcutaneous nodules	١٩
Figure ٢: BM smear of M٠ blast (X١٠٠٠).....	٢٤
Figure ٣: BM smear of M١ blast (x١٠٠٠).....	٢٤
Figure ٤: BM smear of M٢ blast (x١٠٠٠).....	٢٤
Figure ٥: BM smear of M٣ blast (X١٠٠٠).....	٢٥
Figure ٦: BM smear of M٣v blast (X١٠٠٠).....	٢٥
Figure ٧: BM smear of M٤ blast (X١٠٠٠)	٢٥
Figure ٨: BM smear of M٥a blast (X١٠٠٠)	٢٦
Figure ٩: The peroxidase reaction: the image shows a weakly positive blast (١), strongly positive eosinophil (٢), and positive myelocyte (٣).....	٢٨
Figure ١٠: Schematic representation of human Fc receptors	٥٠
Figure ١١: Human Fcγ receptors: FcγR I, FcγR II and FcγR III.....	٥٣
Figure ١٢: Flow Cytometry	٦٢
Figure ١٣: Analysis of human peripheral blood cells by flow cytometry.....	٦٣
Figure ١٤: Analysis of M.Abs by FCM	٦٣
Figure ١٥: ROC curve showing the best cut-off value for CD٦٤	٨٦
Figure ١٦: Survival analysis by Kaplan-Meier curve	٨٦
Figure ١٧: Histogram showing the CD expression of monocytic versus non-monocytic groups of AML	٨٩
Figure ١٨: Histogram showing CD٦٤ expression among studied FAB subclasses of AML	٩٠
Figure ١٩: Histogram showing CD٦٤ expression in monocytic versus non-monocytic groups of studied AML.....	٩١
Figure ٢٠: Histogram showing CD١٤, CD١٥ and CD٦٤ expression in AML-M٤ and M٥ subgroups.....	٩٣

INTRODUCTION

Acute myeloid leukemia (AML) is a marrow-based clonal malignant disease of hematopoietic tissue, in which there is a replacement of normal bone marrow (BM) with abnormal primitive hematopoietic cells (*Chee, ٢٠١١*). It arises because of somatic mutation in pluripotent stem cells or slightly more differentiated progenitor cells, resulting in overgrowth of myeloblasts and other immature cells of myeloid lineage at the expense of other hematopoietic cells (*Byrd, ٢٠١١*).

According to morphology, French-American-British (FAB) group divided AML into eight subtypes designated M٠ through M٧, based on the type of cells from which leukemia developed (*Miller and Pihan, ٢٠٠٩*).

The World Health Organization (WHO) classification (٢٠٠٨) for hematopoietic neoplasm utilizes not only morphological findings but also all available information including genetic, immunophenotypic, biological and clinical features to define specific disease entities (*Advani, ٢٠١١*).

AML is recognized as a heterogeneous molecular disease displaying characteristic patterns of surface antigens (*Rowe, ٢٠٠٩*). Flowcytometric immunopheno-

typing is widely used in diagnosis and subclassification of AML, and hence it plays an important role in instituting proper treatment plans (*Dunphy, 2010*).

CD11c is a monocyte-associated antigen most widely used to identify AML with monocytic differentiation, however, it is observed that it is frequently diminished or absent in such cases (*Krasinskas et al., 2009*).

CD16 is a type of integral membrane glycoprotein known as Fc gamma receptor 3 (FCγR3), and constitutively found only on macrophages and mono-cytes (*Nimmerjahn and Ravetch, 2009*). Several recent studies concluded that CD16 is highly sensitive and specific in distinguishing AML with monocytic component from other AML classes (*Dunphy et al., 2010 and Bruze, 2010*).

AIM OF THE WORK

The aim of this study was to investigate the value of CD τ_4 expression in AML patients, to detect whether it can distinguish AML cases with monocytic differentiation, and to correlate its expression with different prognostic factors.